1228 related articles for article (PubMed ID: 30085333)
21. Sensor-Integrated Microfluidic Approaches for Liquid Biopsies Applications in Early Detection of Cancer.
Sierra J; Marrugo-Ramirez J; Rodríguez-Trujillo R; Mir M; Samitier J
Sensors (Basel); 2020 Feb; 20(5):. PubMed ID: 32121271
[TBL] [Abstract][Full Text] [Related]
22. Metastatic Melanoma: Liquid Biopsy as a New Precision Medicine Approach.
Ricciardi E; Giordani E; Ziccheddu G; Falcone I; Giacomini P; Fanciulli M; Russillo M; Cerro M; Ciliberto G; Morrone A; Guerrisi A; Valenti F
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835424
[TBL] [Abstract][Full Text] [Related]
23. A headlight on liquid biopsies: a challenging tool for breast cancer management.
Massihnia D; Perez A; Bazan V; Bronte G; Castiglia M; Fanale D; Barraco N; Cangemi A; Di Piazza F; Calò V; Rizzo S; Cicero G; Pantuso G; Russo A
Tumour Biol; 2016 Apr; 37(4):4263-73. PubMed ID: 26790442
[TBL] [Abstract][Full Text] [Related]
24. Potential of circulating tumor cells as blood-based biomarkers in cancer liquid biopsy.
Schlange T; Pantel K
Pharmacogenomics; 2016 Feb; 17(3):183-6. PubMed ID: 26799583
[No Abstract] [Full Text] [Related]
25. Digital PCR-based evaluation of nucleic acid extraction kit performance for the co-purification of cell-free DNA and RNA.
Deleu J; Schoofs K; Decock A; Verniers K; Roelandt S; Denolf A; Verreth J; De Wilde B; Van Maerken T; De Preter K; Vandesompele J
Hum Genomics; 2022 Dec; 16(1):73. PubMed ID: 36587211
[TBL] [Abstract][Full Text] [Related]
26. Longitudinal Multi-Parametric Liquid Biopsy Approach Identifies Unique Features of Circulating Tumor Cell, Extracellular Vesicle, and Cell-Free DNA Characterization for Disease Monitoring in Metastatic Breast Cancer Patients.
Keup C; Suryaprakash V; Storbeck M; Hoffmann O; Kimmig R; Kasimir-Bauer S
Cells; 2021 Jan; 10(2):. PubMed ID: 33494385
[TBL] [Abstract][Full Text] [Related]
27. Advances in liquid biopsy-based markers in NSCLC.
Ren XD; Su N; Sun XG; Li WM; Li J; Li BW; Li RX; Lv J; Xu QY; Kong WL; Huang Q
Adv Clin Chem; 2023; 114():109-150. PubMed ID: 37268331
[TBL] [Abstract][Full Text] [Related]
28. Liquid biopsy in lung cancer management.
Irofei Zamfir MA; Buburuzan L; Hudiţă A; Gălăţeanu B; Ginghină O; Ion D; Motaş N; Ardeleanu CM; Costache M
Rom J Morphol Embryol; 2022; 63(1):31-38. PubMed ID: 36074665
[TBL] [Abstract][Full Text] [Related]
29. Cell-free and circulating tumor cell-based biomarkers in men with metastatic prostate cancer: Tools for real-time precision medicine?
Miyamoto DT; Lee RJ
Urol Oncol; 2016 Nov; 34(11):490-501. PubMed ID: 27771279
[TBL] [Abstract][Full Text] [Related]
30. Circulating epigenetic biomarkers in lung malignancies: From early diagnosis to therapy.
Tomasetti M; Amati M; Neuzil J; Santarelli L
Lung Cancer; 2017 May; 107():65-72. PubMed ID: 27312601
[TBL] [Abstract][Full Text] [Related]
31. Isolation and enrichment of circulating biomarkers for cancer screening, detection, and diagnostics.
Hyun KA; Kim J; Gwak H; Jung HI
Analyst; 2016 Jan; 141(2):382-92. PubMed ID: 26588824
[TBL] [Abstract][Full Text] [Related]
32. A Targeted Q-PCR-Based Method for Point Mutation Testing by Analyzing Circulating DNA for Cancer Management Care.
Thierry AR
Methods Mol Biol; 2016; 1392():1-16. PubMed ID: 26843041
[TBL] [Abstract][Full Text] [Related]
33. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.
Jovelet C; Ileana E; Le Deley MC; Motté N; Rosellini S; Romero A; Lefebvre C; Pedrero M; Pata-Merci N; Droin N; Deloger M; Massard C; Hollebecque A; Ferté C; Boichard A; Postel-Vinay S; Ngo-Camus M; De Baere T; Vielh P; Scoazec JY; Vassal G; Eggermont A; André F; Soria JC; Lacroix L
Clin Cancer Res; 2016 Jun; 22(12):2960-8. PubMed ID: 26758560
[TBL] [Abstract][Full Text] [Related]
34. A biocomposite-based rapid sampling assay for circulating cell-free DNA in liquid biopsy samples from human cancers.
Koo B; Jun E; Liu H; Kim EJ; Park YY; Lim SB; Kim SC; Shin Y
Sci Rep; 2020 Sep; 10(1):14932. PubMed ID: 32913285
[TBL] [Abstract][Full Text] [Related]
35. Liquid biopsy in gastric cancer: predictive and prognostic biomarkers.
Zhang Z; Wu H; Chong W; Shang L; Jing C; Li L
Cell Death Dis; 2022 Oct; 13(10):903. PubMed ID: 36302755
[TBL] [Abstract][Full Text] [Related]
36. Liquid biopsy: will it be the 'magic tool' for monitoring response of solid tumors to anticancer therapies?
Gingras I; Salgado R; Ignatiadis M
Curr Opin Oncol; 2015 Nov; 27(6):560-7. PubMed ID: 26335664
[TBL] [Abstract][Full Text] [Related]
37. Blood has never been thicker: Cell-free DNA fragmentomics in the liquid biopsy toolbox of B-cell lymphomas.
Meriranta L; Pitkänen E; Leppä S
Semin Hematol; 2023 Jul; 60(3):132-141. PubMed ID: 37455222
[TBL] [Abstract][Full Text] [Related]
38. Bioplatforms in liquid biopsy: advances in the techniques for isolation, characterization and clinical applications.
Shah UJ; Alsulimani A; Ahmad F; Mathkor DM; Alsaieedi A; Harakeh S; Nasiruddin M; Haque S
Biotechnol Genet Eng Rev; 2022 Oct; 38(2):339-383. PubMed ID: 35968863
[TBL] [Abstract][Full Text] [Related]
39. Liquid Profiling of Circulating Nucleic Acids as a Novel Tool for the Management of Cancer Patients.
Holdenrieder S
Adv Exp Med Biol; 2016; 924():53-60. PubMed ID: 27753019
[TBL] [Abstract][Full Text] [Related]
40. Biosensors for liquid biopsy: circulating nucleic acids to diagnose and treat cancer.
Bellassai N; Spoto G
Anal Bioanal Chem; 2016 Oct; 408(26):7255-64. PubMed ID: 27497966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
